![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
TK Chang, G Chen and DJ Waxman
Department of Biology, Boston University, Massachusetts, USA.
The anticancer drug and alkylating agent thiotepa is metabolized by oxidative desulfuration to yield the alkylating metabolite N,N',N"- triethylenephosphoramide (TEPA) in a reaction that is catalyzed by specific liver cytochrome P450 (CYP) enzymes, including CYP2B1, the major phenobarbital-inducible P450 of rat liver, and CYP2C11, a constitutively expressed, male-specific form. The present study investigates the potential for modulating the cytotoxicity and antitumor activity of thiotepa by prior treatment of tumor-bearing rats with the CYP2B1 inducer phenobarbital or the CYP2C11 inhibitor 2- diethylaminoethyl-2,2-diphenylvalerate hydrochloride (SKF-525A) and examines the role of TEPA in the cytotoxicity of thiotepa in vivo. Administration of thiotepa to adult male rats bearing 9L gliosarcoma, grown s.c., resulted in dose-dependent cytotoxicity (ED90 approximately 12 mg/kg i.v., single dose), as determined by a tumor excision/in vitro colony formation assay carried out 24 hr after drug treatment. Tumor growth delay experiments revealed that thiotepa (5 mg/kg) inhibited 9L tumor growth over a 5- to 7-day period after alkylating agent treatment and this effect was accompanied by moderate body weight loss. Pretreatment with phenobarbital, under conditions in which liver CYP2B1 levels and liver microsomal thiotepa desulfuration to yield TEPA are both markedly increased, did not alter thiotepa's short-term (24-hr) cytotoxicity, as judged by a tumor excision assay, nor did it affect the extent of bone marrow toxicity associated with drug treatment. However, phenobarbital did block the tumor growth delay effect of thiotepa and it also attenuated the body weight loss that occurred during the first 5 days after drug treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  G. Singh, P. H. Driever, and J. W. Sander Cancer risk in people with epilepsy: the role of antiepileptic drugs Brain, January 1, 2005; 128(1): 7 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. de Jonge, A. D.R. Huitema, A. C. Tukker, S. M. van Dam, S. Rodenhuis, and J. H. Beijnen Accuracy, Feasibility, and Clinical Impact of Prospective Bayesian Pharmacokinetically Guided Dosing of Cyclophosphamide, Thiotepa, and Carboplatin in High-Dose Chemotherapy Clin. Cancer Res., January 1, 2005; 11(1): 273 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Rae, N. V. Soukhova, D. A. Flockhart, and Z. Desta Triethylenethiophosphoramide Is a Specific Inhibitor of Cytochrome P450 2B6: Implications for Cyclophosphamide Metabolism Drug Metab. Dispos., May 1, 2002; 30(5): 525 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Glantz, B. F. Cole, P. A. Forsyth, L. D. Recht, P. Y. Wen, M. C. Chamberlain, S. A. Grossman, and J. G. Cairncross Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology, May 23, 2000; 54(10): 1886 - 1893. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. van Maanen, I. M. Tijhof, J. M. A. Damen, C. Versluis, J. J. K. van den Bosch, A. J. R. Heck, S. Rodenhuis, and J. H. Beijnen A Search for New Metabolites of N,N',N''-Triethylenethiophosphoramide Cancer Res., September 1, 1999; 59(18): 4720 - 4724. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
